Introduction
============

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide.[@b1-ott-11-6555] Hepatic resection and transplantation are considered the best treatments for early-stage patients with high probability of long-term survival.[@b2-ott-11-6555] Radiofrequency ablation (RFA) is emerging as an effective local treatment for curative intent in patients with small HCC with a diameter \<3 cm.[@b3-ott-11-6555],[@b4-ott-11-6555] Several meta-analyses[@b5-ott-11-6555],[@b6-ott-11-6555] have shown that RFA and surgical resection have a comparable impact on overall (OS) and recurrence-free survival (RFS). Given the different therapeutic options that occur in patients with HCC in the initial stage, it is absolutely essential to identify prognostic factors that can predict the possibility of relapse. There are several works published by RFA. All these studies have a heterogeneous duration of patient groups, to tell the reason, it is difficult to compare them. Furthermore, to date, neither randomized studies on RFA vs best supportive care nor meta-analyses evaluating OS and RFS have been completed on RFA patients alone.

The purpose of this meta-analysis was to evaluate prognostic factors of OS and RFS in patients treated with RFA, with the aim to identify parameters that can help clinicians in the therapeutic choice, and determine stratification factors for future studies in this subset of patients.

Materials and methods
=====================

Study design and inclusion criteria
-----------------------------------

Clinical trials on the prognostic factors of RFA in HCC patients were considered, excluding randomized controlled trials comparing RFA and surgery, studies with insufficient data to estimate the outcomes, and studies on RFA with microwave and ethanol. A primary analysis was planned to evaluate the clinical prognostic factor of OS. RFS was the secondary aim. OS was defined as the time interval between the day of start of treatment until the day of death or last follow-up visit. The RFS was defined as the observation time during the follow-up period during which the patient developed a intrahepatic distant recurrence, extrahepatic recurrence, or death.

Search strategy
---------------

We conducted a bibliographic search of the PubMed, Embase, Cochrane Library. Keywords used included "radiofrequency AND hepatocellular carcinoma", "radiofrequency AND liver cancer". Articles published in English until September 2017 and reporting data of studies conducted on human participants were retrieved. Relevant reviews and meta-analyses of loco-regional treatments of unresectable HCC were also examined for potential suitable studies and data. The 2000--2017 proceedings of the Annual Meeting of the American Society of Clinical Oncology (ASCO and ASCO Gastrointerstinal), European Society of Clinical Oncology (ESMO and ESMO Gastrointerstinal), European Association for the Study of the Liver, American Association for the Study of Liver Diseases, and International Liver Cancer Association were systematically reviewed for relevant unpublished data.

The computer search was supplemented with a manual search of the primary studies referenced in all of the retrieved review articles. When the results of a study were reported in multiple subsequent analyses, only the most recent and complete version was considered.

Data extraction and management
------------------------------

Two review authors (ACG and MV) independently screened the titles of all the selected studies, and read the abstracts of potentially eligible papers. Whenever discrepancies in trial search or selection occurred between the 2 review authors, they were discussed with a third review author (FGF) to reach an agreement. All selected trials published as full-text articles in peer-reviewed journals were analyzed and classified using the Newcastle--Ottawa Quality Assessment Scale for Cohort Studies. ACG and MV independently performed the qualitative and quantitative analysis of the selected articles. Whenever discrepancies occurred, they were discussed with FGF to reach an agreement.

Statistical analysis
--------------------

All analyses were carried out using Stata version 15.0 (Stata Corporation, College Station, TX, USA). HR reported in each study was used as an outcome measure of the prognostic value. The summary estimates were generated using a fixed-effect model (Mantel--Haenszel method) or a random-effect model[@b49-ott-11-6555] depending on the absence or presence of heterogeneity.

The inter-study heterogeneity was examined by the Cochran's Q and I-squared statistic with an I-squared \>50% representing significant heterogeneity.[@b7-ott-11-6555]

We assessed the potential of publication bias by visually inspecting the funnel plot symmetry and Egger's test for asymmetry.[@b8-ott-11-6555]

Sensitivity analyses were conducted by excluding 1 study at a time and reanalyzing the remaining to test whether the results had changed substantially by any individual study. A value of *P*\<0.05 was regarded as statistically significant for all statistical analyses. All tests were 2-sided.

Results
=======

Study selection and characteristics
-----------------------------------

[Figure 1](#f1-ott-11-6555){ref-type="fig"} reports the search strategy used in this meta-analysis. Thirty-four[@b9-ott-11-6555]--[@b42-ott-11-6555] studies published between 2003 and 2017 were analyzed. They included 11,216 HCC patients treated with RFA. The characteristics of the study are gathered in [Table 1](#t1-ott-11-6555){ref-type="table"}.

Overall survival
----------------

The analysis of liver functionality showed that Child-- Pugh B vs Child--Pugh A (HR =2.32; 95% CI: 2.201--2.69; *P*\<0.0001) ([Figure 2A](#f2-ott-11-6555){ref-type="fig"}), increase in bilirubin (HR =1.03; 95% CI: 1.01--1.04; *P*\<0.0001) ([Figure 2B](#f2-ott-11-6555){ref-type="fig"}), presence of Portosystemic collaterals (HR =1.54; 95% CI: 1.31--1.82; *P*\<0.0001) ([Figure 2C](#f2-ott-11-6555){ref-type="fig"}), and albumin-bilirubin (ALBI) score 1 vs 0 (HR =2.69; 95% CI: 2.10--3.44; *P*\<0.0001) ([Figure 2D](#f2-ott-11-6555){ref-type="fig"}) were predictive of poor OS. Decrease in prothrombin activity (HR =0.97; 95% CI: 0.96--0.99; *P*\<0.0001) ([Figure 2E](#f2-ott-11-6555){ref-type="fig"}) and increase in albumin (HR =0.90; 95% CI: 0.87--0.94; *P*\<0.0001) ([Figure 2F](#f2-ott-11-6555){ref-type="fig"}) were predictive of better OS.

Tumor size was not predictive of OS (HR =1.01; 95% CI: 0.99--1.03; *P*=0.269) ([Figure 3A](#f3-ott-11-6555){ref-type="fig"}) when considered as a continuous variable. Yet, it was predictive of OS when considered as a cutoff value. An either size cutoff of 2 or 3 cm was predictive of poor OS (\>2 cm, HR =1.41; 95% CI: 1.23--1.61; *P*\<0.0001, [Figure 3B](#f3-ott-11-6555){ref-type="fig"}; \>3 cm, HR =1.43; 95% CI: 1.17--1.74; *P*\<0.0001, [Figure 3C](#f3-ott-11-6555){ref-type="fig"}). When considering the number of nodules, the presence of \>1 nodules (HR =1.59; 95% CI: 1.46--1.74; *P*\<0.0001) ([Figure 3D](#f3-ott-11-6555){ref-type="fig"}) was predictive of poor OS.

Gender was not predictive of OS (male vs female HR =1.07; 95% CI: 0.99--1.15; *P*=0.091) ([Figure S1A](#SD1-ott-11-6555){ref-type="supplementary-material"}), while an older age (HR =1.02; 95% CI: 1.01--1.03; *P*\<0.0001) ([Figure S1B](#SD1-ott-11-6555){ref-type="supplementary-material"}) and an age \>65 years (HR =1.73; 95% CI: 1.40--2.12; *P*\<0.0001) ([Figure S1C](#SD1-ott-11-6555){ref-type="supplementary-material"}) were predictive of poor OS.

Data showed that an alpha-fetoprotein cutoff of 20 ng/mL (\>20 ng/mL vs \<20 ng/mL HR =1.46; 95% CI: 1.25--1.70; *P*\<0.0001) ([Figure 4A](#f4-ott-11-6555){ref-type="fig"}) was predictive of poor prognosis, whereas alpha-fetoprotein cutoffs of 200 ng/mL (\>200 ng/mL vs \<200 ng/mL HR =1.21; 95% CI: 0.74--1.95; *P* 0.475) ([Figure 4B](#f4-ott-11-6555){ref-type="fig"}) and 400 ng/mL (\>400 ng/mL vs \<400 ng/mL HR =1.30; 95% CI: 0.91--1.85; *P* 0.332) ([Figure 4C](#f4-ott-11-6555){ref-type="fig"}) were not predictive of poor prognosis.

As for etiology, data show that hepatitis B virus (HBV) infection (HBV infection vs no HBV infection HR =0.86; 95% CI: 0.77--0.97; *P* 0.011) ([Figure 5A](#f5-ott-11-6555){ref-type="fig"}) was predictive of good prognosis, whereas patients with hepatitis C virus (HCV) infection vs patients without HCV infection showed no statistically significant difference (HR =1.14; 95% CI: 0.95--1.36; *P* 0.147) ([Figure 5B](#f5-ott-11-6555){ref-type="fig"}).

Finally, neutrophil--lymphocyte ratio (NLR) was predictive of poor prognosis (high vs low HR =1.91; 95% CI: 1.35--2.70; *P*\<0.0001) ([Figure S1D](#SD1-ott-11-6555){ref-type="supplementary-material"}).

Recurrence-free survival
------------------------

The analysis of liver functionality showed that only Child-- Pugh B vs Child--Pugh A was predictive of poor RFS (HR =1.24; 95% CI: 1.11--1.40; *P*\<0.0001) ([Figure 6A](#f6-ott-11-6555){ref-type="fig"}). Bilirubin, albumin, prothrombin activity, and portosystemic collaterals were not predictive of RFS ([Figure S2A--D](#SD2-ott-11-6555){ref-type="supplementary-material"}).

Tumor size was not predictive of RFS when the size of the nodule was considered as a continuous variable (HR =1.00; 95% CI: 0.99--1.01; *P* 0.465) ([Figure 6B](#f6-ott-11-6555){ref-type="fig"}). Yet, when the cutoff was considered, tumor sizes \>2 cm vs \<2 cm (HR =1.77; 95% CI: 1.47--2.12; *P*\<0.0001) ([Figure 6C](#f6-ott-11-6555){ref-type="fig"}) and \>3 cm vs \<3 cm (HR =1.31; 95% CI: 1.13--1.53; *P*\<0.0001) ([Figure 6D](#f6-ott-11-6555){ref-type="fig"}) were predictive of poor RFS. When considering the number of nodules, the presence of \>1 nodule (HR =1.62; 95% CI: 1.47--1.78; *P*\<0.0001) ([Figure 6E](#f6-ott-11-6555){ref-type="fig"}) was predictive of poor RFS.

Gender was not predictive of RFS (male vs female HR =1.05; 95% CI: 0.96--1.15; *P* 0.243) ([Figure S2E](#SD2-ott-11-6555){ref-type="supplementary-material"}), whereas an older age (HR =1.01, 95% CI: 1.00--1.01; *P* 0.021) ([Figure S2F](#SD2-ott-11-6555){ref-type="supplementary-material"}) was predictive of poor RFS.

Data showed that an alpha-fetoprotein cutoff of 400 ng/mL (\>400 ng/mL vs \<400 ng/mL HR =1.16; 95% CI: 0.93--1.46; *P* 0.186) ([Figure 6F](#f6-ott-11-6555){ref-type="fig"}) was not predictive of RFS.

As for etiology, HBV infection (HBV infection vs no HBV infection HR =1.16; 95% CI: 1.03--1.31; *P* 0.012) ([Figure 7A](#f7-ott-11-6555){ref-type="fig"}) was predictive of poor RFS. The presence of HCV infection vs no HCV infection (HR =1.15, 95% CI: 1.04--1.27; *P* 0.008) ([Figure 7B](#f7-ott-11-6555){ref-type="fig"}) was predictive of poor RFS.

Finally, NLR was not predictive of RFS (high vs low HR =1.28; 95% CI: 0.98--1.69; *P* 0.075).

Publication bias
----------------

The funnel plots were evaluated and seemed symmetrical. No publication bias was observed and Egger's tests for asymmetry were not significant (*P*-value=0.851 for OS, *P*=0.806 for RFS and *P*=0.573).

Sensitivity analysis
--------------------

Sensitivity analyses were performed in order to examine the stability of the results (data not shown). The pooled HRs suggest that results were statistically reliable because they were not changed substantially omitting 1 study at a time.

Discussion
==========

In this meta-analysis of \>10,000 individuals, we evaluated what factors are capable of predicting OS and RFS in HCC patients treated with RFA. As most studies and meta-analyses considered RFA vs surgery, this is the first meta-analysis to have evaluated only clinical or laboratory parameters in this subset of patients without comparing with surgery.

Our study showed that Child--Pugh B was a significant predictor of poor OS (HR =2.32) and RFS (HR =1.24). Our data showed that other liver function parameters are also highly predictive of poor OS (bilirubin, presence of portosystemic circles, prothrombin, and albumin), whereas only Child--Pugh B vs Child--Pugh A was predictive of poor RFS. The severity of the underlying liver disease may also be a risk factor for the development and recurrence of HCC, suggesting the importance of the role of the liver function in these patients. A recent study by Wei-Yu Kao et al[@b12-ott-11-6555] evaluated ALBI grade and platelet-albumin-bilirubin grade as prognostic and predictive indexes in patients treated with RFA. The data highlighted a significant difference in OS between Child--Pugh A and ALBI grade 1 vs Child-- Pugh A and ALBI grade 1 and 2. This study showed for the first time that ALBI grade can better stratify these patients. Their results have also been confirmed by Oh Is et al[@b41-ott-11-6555] and CH Lo et al.[@b42-ott-11-6555] Also, our meta-analysis confirms that ALBI grade is currently one of the best indexes for predicting survival in this patient subset. As shown by other works at different disease stages,[@b43-ott-11-6555]--[@b45-ott-11-6555] ALBI grade is better predictive index than Child--Pugh, as the latter is composed of 5 arbitrary parameters, whereas the former is formed by only 2 non-arbitrary parameters (albumin and bilirubin). Interestingly, this meta-analysis showed that the presence of the portosystemic collateral is a predictive factor of OS. As for liver resection, the presence of portal hypertension is a well-known predictor for survival, regardless of the Child--Pugh class.[@b46-ott-11-6555],[@b47-ott-11-6555]

Another factor evaluated in this meta-analysis was the pre RFA tumor size. The size of the nodules, taken as a continuous variable, was not predictive of either OS or RFS, because many studies included in the meta-analysis considered only small nodules. Conversely, when we evaluated the size of the nodule as a cutoff value, we observed that the maximum benefit of RFA was reached when nodules were \<2 cm, confirming the literature data[@b48-ott-11-6555] and supporting the choice of RFA as the first treatment option. For tumors \>2 cm, other factors must also be considered. As for the number of nodules, our meta-analysis showed that the presence of multiple nodules is a negative prognostic index both in terms of OS (HR =1.59) and RFS (HR =1.62): therefore, in most nodular patients, especially if operable, RFA is not recommended.

In regard to etiology, our results showed that HBV-positive patients have better OS and worse RFS (HR =1.16) when treated with RFA. These data, however, are difficult to explain, particularly for the contrasting data between OS and RFS. In all considered studies, etiology was regarded as presence or absence of HBV or HCV infection. Only in 1 study,[@b31-ott-11-6555] the different etiologies were directly compared, highlighting our data as a benefit in terms of OS in HBV-positive patients compared with HCV-positive patients with a 56% reduction in death risk.

Concerning the predictive role of alpha fetoprotein, our meta-analysis revealed that only a cutoff of 20 ng/mL can predict OS and RFS outcomes in these patients.

Although NLR might play a role in predicting OS and RFS, data are currently limited and cannot be employed in normal clinical practice.

Limitations
===========

Among the limitations of our meta-analysis are the low number of published studies considered for some subgroup analyses by prognostic factor, and the consideration of studies only reporting HR and 95% CI, thus potentially introducing further bias. Another limitation is that in this is a meta-analysis of aggregate patient data and not of individual patient data.

Conclusion
==========

Our meta-analysis highlighted that the maximum benefit of RFA in terms of OS and RFS is reached when all the following features are present: Child--Pugh A, ALBI score 1, single-nodule tumor sized \<2 cm, and alpha-fetoprotein \<20 ng/mL. The role of the different etiologies still remains to be clarified. These clinical/laboratory data should also be used to better stratify patients in future RFA randomized trials.
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Forest plots for overall survival for male vs female (**A**), age as continue variable (**B**), age 65 years (**C**) and neutrophil--lymphocyte ratio (**D**).
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Forest plots for recurrence free survival for bilirubin (**A**), albumin (**B**), prothrombin activity (**C**), portosystemic collaterals (**D**), male vs female (**E**), and age (**F**).
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![Forest plots for recurrence-free survival showing HBV infection (**A**); HCV infection (**B**).\
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###### 

Characteristics of the studies included in the meta-analysis

  Author                                Date of publication   Data of collection    Number of patients   Study period   \% Child-- Pugh A   \% of patients with \>1 nodule   \% liver etiology (HBV; HCV; alcohol; metabolic; other)   Follow-up                The Newcastle-- Ottawa scale (NOS); total score
  ------------------------------------- --------------------- --------------------- -------------------- -------------- ------------------- -------------------------------- --------------------------------------------------------- ------------------------ -------------------------------------------------
  Lee et al[@b9-ott-11-6555]            2014                  Retrospective study   162                  2006--2007     84.6                10.5                             (72.9; 21.6; 3.7; NR; NR)                                 Mean 50.3 ± 19.9         8
  El-Fattah et al[@b10-ott-11-6555]     2016                  SEER registries       1,981                2004--2012     NR                  26.2                             NR                                                        Median 20; range 9--38   7
  Zhang et al[@b11-ott-11-6555]         2017                  Retrospective study   410                  2005--2016     97.7                NR                               NR                                                        NR                       7
  Kao et al[@b12-ott-11-6555]           2017                  Retrospective study   622                  2002--2013     86.5                19.1                             (47.7; 43.2; NR; NR; 9.1)                                 Median 35.7              9
  Cho et al[@b13-ott-11-6555]           2016                  Retrospective study   438                  2006--2009     85.9                NR                               (72.4; 16.2; 3.9; NR; 6.4)                                Median 68.4              8
  Kang et al[@b14-ott-11-6555]          2017                  Retrospective study   572                  2006--2012     81.8                NR                               (63.6; 14.4; NR; NR; 10.5)                                Median 57.9              8
  Lin et al[@b15-ott-11-6555]           2015                  Retrospective study   70                   2009--2011     85.7                46.9                             (45.7; 44.3; NR; NR; NR)                                  Median 20.7 ± 10.3       9
  Yang et al[@b16-ott-11-6555]          2016                  Retrospective study   316                  2000--2013     77                  21.6                             (86.6; 10.2; 1.9; NR; 1.3)                                Mean 20.4                9
  Dohi et al[@b17-ott-11-6555]          2016                  Retrospective study   357                  2001--2013     84                  31.4                             (12.1; 81.4; NR; NR; NR)                                  NR                       8
  Gao et al[@b18-ott-11-6555]           2015                  Retrospective study   184                  2005--2013     51                  NR                               (87; 9; NR; NR; 2)                                        Median 65                9
  Montasser et al[@b20-ott-11-6555]     2014                  Retrospective study   105                  2007--2011     NR                  28.6                             (2.8; 94.2; NR; NR; 1.9)                                  Mean 20.1 ± 10.67        8
  Facciorusso et al[@b21-ott-11-6555]   2014                  Not indicated         103                  2005--2010     83.4                NR                               (22.3; 60.1; NR; NR; 17.6)                                NR                       7
  Dan et al[@b22-ott-11-6555]           2013                  Retrospective study   178                  2005--2008     83.9                NR                               (89.2; NR; NR; NR; NR)                                    Median 52.7              8
  Lee et al[@b23-ott-11-6555]           2014                  Retrospective study   161                  2006--2007     86.9                22.6                             (72; 19; NR; NR; 6)                                       Mean 45 ± 21             8
  Moribata et al[@b24-ott-11-6555]      2012                  Retrospective study   97                   2001--2006     63.6                NR                               (NR; 88.6; NR; NR; NR)                                    NR                       7
  Lu et al[@b25-ott-11-6555]            2012                  Not indicated         661                  2004--2006     NR                  NR                               (NR; NR; NR; NR; NR)                                      Median 41.9              8
  Kao et al[@b26-ott-11-6555]           2012                  Retrospective study   313                  2002--2009     87.5                16                               (44.7; 47.2; NR; NR; NR)                                  Median 26.7 ± 19.1       7
  Chen et al[@b27-ott-11-6555]          2012                  Retrospective study   158                  2003--2010     84.8                19.7                             (36; NR; NR; NR; NR)                                      Mean 34                  8
  Giorgio et al[@b28-ott-11-6555]       2011                  Not indicated         143                  2005--2010     50                  NR                               (42.9; 57; NR; NR; NR)                                    Mean 37                  8
  Goto et al[@b29-ott-11-6555]          2011                  Retrospective study   69                   2000--2007     78.2                NR                               (23.1; NR; NR; NR; NR)                                    Median 17                9
  Chen et al[@b30-ott-11-6555]          2011                  Retrospective study   135                  2003--2009     NR                  16.8                             (34.3; 56.3; NR; NR; NR)                                  Mean 32.2                8
  Rossi et al[@b31-ott-11-6555]         2011                  Retrospective study   706                  1998--2008     76.2                21.7                             (4.5; 85.9; 4.2; NR; 2.4)                                 Median 29                7
  Takahashi et al[@b32-ott-11-6555]     2010                  Retrospective study   461                  2000--2007     77                  37                               (5.4; 85.2; NR; NR; NR)                                   NR                       7
  Imai et al[@b33-ott-11-6555]          2010                  Not indicated         24                   2006--2007     83.3                NR                               (NR; NR; NR; NR; NR)                                      Mean 12.3                7
  dal Bello et al[@b34-ott-11-6555]     2010                  Retrospective study   207                  2000--2008     91.8                20.3                             (NR; NR; NR; NR; NR)                                      Median 36                7
  N'Kontchou et al[@b35-ott-11-6555]    2009                  Retrospective study   235                  2001--2007     85                  22                               (7; 50; 37; NR; 4)                                        Mean 27                  8
  Chinnaratha et al[@b36-ott-11-6555]   2015                  Retrospective study   539                  2006--2012     73                  NR                               (18.3; 33.3; 15.1; 8.7; NR)                               Mean 13.5                8
  Kao et al[@b37-ott-11-6555]           2012                  Retrospective study   258                  NR             87.6                19.5                             (42.9; 47.6; NR; NR; NR)                                  Median 28.5              8
  Lencioni et al[@b38-ott-11-6555]      2003                  Prospective study     102                  NR             87                  23                               (12; 42; 15; NR; 6)                                       Mean 22.9                9
  Kao et al[@b39-ott-11-6555]           2011                  Retrospective study   190                  2002--2007     84.2                20                               (47.6; 45.7; NR; NR; NR)                                  Median 30.7              8
  Tajiri et al[@b40-ott-11-6555]        2016                  Retrospective study   163                  2003--2014     79.1                NR                               (15.9; 68; NR; NR; NR)                                    NR                       7
  Oh et al[@b41-ott-11-6555]            2017                  Retrospective study   368                  2007--2012     100                 NR                               (78; NR; NR; NR; NR)                                      Median 61                8
  Lo et al[@b42-ott-11-6555]            2017                  Retrospective study   152                  2007--2015     78.3                NR                               (53.3; 30.9; NR; NR; NR)                                  Median 10                8

**Abbreviations:** HBV, hepatitis B virus; HCV, hepatitis C virus; NR, not reported; SEER, Surveillance, Epidemiology, and End Results.
